- Home
- SUI vs GMAB Comparison
SUI vs GMAB Comparison
Compare SUI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUI
- GMAB
- Stock Information
- Founded
- SUI 1975
- GMAB 1999
- Country
- SUI United States
- GMAB Denmark
- Employees
- SUI N/A
- GMAB N/A
- Industry
- SUI Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SUI Real Estate
- GMAB Health Care
- Exchange
- SUI Nasdaq
- GMAB Nasdaq
- Market Cap
- SUI 16.0B
- GMAB 13.9B
- IPO Year
- SUI 1993
- GMAB N/A
- Fundamental
- Price
- SUI $126.81
- GMAB $22.10
- Analyst Decision
- SUI Buy
- GMAB Buy
- Analyst Count
- SUI 14
- GMAB 7
- Target Price
- SUI $137.57
- GMAB $37.80
- AVG Volume (30 Days)
- SUI 1.3M
- GMAB 960.0K
- Earning Date
- SUI 07-30-2025
- GMAB 08-11-2025
- Dividend Yield
- SUI 3.28%
- GMAB N/A
- EPS Growth
- SUI 1883.93
- GMAB 276.80
- EPS
- SUI 10.23
- GMAB 18.36
- Revenue
- SUI $3,217,100,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- SUI N/A
- GMAB $21.64
- Revenue Next Year
- SUI $3.48
- GMAB $15.57
- P/E Ratio
- SUI $12.40
- GMAB $1.20
- Revenue Growth
- SUI 17.94
- GMAB 25.43
- 52 Week Low
- SUI $109.22
- GMAB $17.24
- 52 Week High
- SUI $147.83
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- SUI 56.42
- GMAB 51.96
- Support Level
- SUI $115.53
- GMAB $21.26
- Resistance Level
- SUI $127.44
- GMAB $23.87
- Average True Range (ATR)
- SUI 3.05
- GMAB 0.35
- MACD
- SUI 0.42
- GMAB -0.08
- Stochastic Oscillator
- SUI 94.71
- GMAB 32.21
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 645 properties, which includes 341 manufactured housing communities, 166 residential vehicle communities, and 138 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.